Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

BioSpace

NOVEMBER 9, 2021

Angany entered into collaboration for a series of preclinical studies that will evaluate the safety and efficacy of BP/AH-01, Angany’s lead peanut allergy biological candidate.

Allergies 77

Allergies Vaccination Vaccine 77

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

NY Times

DECEMBER 25, 2020

The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.

Vaccination 145

Vaccination Vaccine Doctors Doctor 145

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. FRIDAY, Dec. FRIDAY, Dec. © 2020 HealthDay.

Allergies 52

Allergies Vaccination Vaccine Immune Response 52

BioTech 365

OCTOBER 7, 2021

Best’s Commentary: Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain Best’s Commentary: Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain SINGAPORE–(BUSINESS WIRE)–Vaccine allergy insurance products launched by Thailand insurers address an important financial (..)

Allergies 52

Allergies Production Vaccination Vaccine 52

NY Times

DECEMBER 18, 2020

Four people so far have had allergic reactions after getting the Pfizer-BioNTech vaccine. Experts say that shouldn’t deter most people from getting a jab.

Allergies 94

Allergies Vaccination Vaccine Clinical Trials 94

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

Medical Xpress

APRIL 13, 2023

In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop have now been published as a report in npj Vaccines.

Vaccination 74

Vaccination Vaccine Allergies Development 74

Medical Xpress

MARCH 2, 2023

Allergic reactions to the Pfizer or Moderna COVID vaccines are very rare, and a new study questions whether many of those that do occur are even real.

Allergies 66

Allergies Vaccination Vaccine Trials 66

Medical Xpress

NOVEMBER 10, 2022

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Vaccination 76

Vaccination Vaccine Allergies 76

pharmaphorum

JANUARY 18, 2021

Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. The clinic in question switched to another lot of Moderna vaccine after closing for a few hours.

Vaccination 136

Vaccination Vaccine Allergies Scientist 136

DM Clinical Research

APRIL 30, 2021

And while this means that most of us can get outside and enjoy the nice weather, it means something different to allergy sufferers. If you have seasonal allergies, then you know how painful and annoying your symptoms can be. Certain symptoms might have you wondering- is it allergies or COVID? Is it Allergies or COVID symptoms?

Allergies 40

Allergies Clinical Research Vaccine Vaccination 40

Pharma Times

JANUARY 6, 2021

Study will take place at Imperial College London

Allergies 104

Allergies Vaccination Vaccine 104

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. A non-temperature stable form of the candidate previously had been tested in several clinical trials.

Immune Response 75

Immune Response Vaccination Vaccine Trials 75

pharmaphorum

DECEMBER 5, 2022

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccination 98

Vaccination Vaccine Antibody Allergies 98

BioSpace

DECEMBER 4, 2020

National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine. Researchers with the U.S.

Vaccination 85

Vaccination Vaccine Allergies Medicine 85

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Scienmag

OCTOBER 14, 2020

A prospective observational study testing the concept of trained immunity for protection from severe COVID-19 reported milder symptoms in COVID patients receiving MMR vaccination, as published in Allergy. Yet what if an existing vaccine […].

Vaccination 59

Vaccination Vaccine Allergies Clinical Trials 59

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 97

Vaccination Vaccine RNA Manufacturing 97

pharmaphorum

MARCH 23, 2021

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. AstraZeneca is preparing to file this and other trial data with the FDA asking for an emergency approval of the vaccine.

Vaccination 98

Vaccination Vaccine Trials Allergies 98

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Source link.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

The Pharma Data

JANUARY 6, 2021

6, 2021 — Cases of anaphylactic shock caused by COVID-19 vaccines are very rare, based on numbers from the first week and a half of vaccinations in the United States, federal public health officials said Wednesday. Seven out of 10 cases occurred within 15 minutes of vaccination. WEDNESDAY, Jan.

Vaccination 52

Vaccination Vaccine Allergies Drugs 52

XTalks

MAY 11, 2022

The US Food and Drug Administration (FDA) announced last week that it has limited the authorized use of Janssen/Johnson & Johnson’s COVID-19 vaccine for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible or clinically appropriate.

Vaccination 89

Vaccination Vaccine Sales Allergies 89

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? How safe and effective are the vaccines?

Vaccination 52

Vaccination Vaccine Allergies Protein 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

BioPharma Reporter

MARCH 23, 2021

The US National Institute of Allergy and Infectious Diseases (NIAID) says it is concerned that AstraZeneca 'may have included outdated informationâ when releasing initial data from its COVID-19 vaccine clinical trial.

Vaccination 52

Vaccination Vaccine Allergies Trials 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 84

Drug Delivery Drugs Immune Response Allergies 84

pharmaphorum

OCTOBER 18, 2021

An FDA advisory committee voted unanimously in favour of a booster dose of Johnson & Johnson’s one-shot COVID-19 vaccine on Friday, as panellists suggested it should have been used as a two-dose regimen from the start. All told, 15 million people in the US have been vaccinated with Ad26.COV2.S,

Vaccination 97

Vaccination Vaccine Allergies Antibody 97

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. A small study from John Hopkins University has shown that a third dose of a COVID-19 vaccine could indeed help immunocompromised patients.

Vaccination 85

Vaccination Vaccine Antibody Immune Response 85

Roots Analysis

MARCH 16, 2023

It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. mRNA Therapeutics and Vaccines Delivery Routes Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens.

Vaccination 52

Vaccination Vaccine DNA Protein 52

XTalks

NOVEMBER 16, 2020

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 The news comes shortly after Pfizer and BioNTech’s mega announcement last week of their COVID-19 vaccine having shown 90 percent efficacy in an ongoing large-scale Phase III trial. The vaccine is given in two doses.

Vaccination 105

Vaccination Vaccine Trials Allergies 105

Scienmag

JULY 23, 2021

Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala. and Troy Randall, Ph.D., write […].

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 58

Manufacturing Vaccination Vaccine Allergies 58